Anabolic effect of phosphogenistein and phosphodaidzein on bone components in rat femoral-metaphyseal tissues in vitro.
The effect of phosphogenistein and phosphodaidzein, which are phosphorylated for the hydroxyl group (OH) at the 7-position of genistein and daidzein, on bone components was investigated. Femoral-metaphyseal tissues obtained from male rats (4 weeks old) were cultured for 24-72 h in Dulbecco's modified Eagle's medium (high glucose, 4.5%) supplemented with antibiotics and bovine serum albumin. The presence of phosphogenistein (10(-5) M) caused a significant increase in calcium content, alkaline phosphatase activity, and deoxyribonucleic acid (DNA) content in bone tissues cultured for 24 h. Phosphodaidzein (10(-5) M) significantly elevated bone calcium and DNA content. These effects were completely prevented by the presence of cycloheximide (10(-6) M), an inhibitor of protein synthesis. When femoral-metaphyseal tissues were cultured for 48 h in the presence of parathyroid hormone (1-34) (PTH; 10(-8) M) or prostaglandin E2 (PGE2; 10(-6) M), bone calcium content was significantly decreased. This decrease was significantly blocked by the presence of phosphogenistein (10(-6) and 10(-5) M) or phosphodaidzein (10(-6) and 10(-5) M). The presence of PTH (10(-8) M) or PGE2 (10(-6) M) caused a significant increase in glucose consumption and lactic acid production by bone tissues. These increases were significantly inhibited by the presence of phosphogenistein (10(-5) M) or phosphodaidzein (10(-5) M), indicating their inhibitory effect on bone resorption. The present study has demonstrated that both phosphogenistein and phosphodaidzein have an anabolic effect on bone metabolism in rat femoral-metaphyseal tissues in vitro.
Yamaguchi
Masayoshi
M
Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, 52-1 Yada, Shizuoka 422-8526, Japan.
Ma
Zhong Jie
ZJ
Fushimi
Takashi
T
D000469:Alkaline Phosphatase / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001862:Bone Resorption / Q000378:metabolism / Q000517:prevention & control; D002118:Calcium / Q000378:metabolism; D046508:Culture Techniques; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA / Q000032:analysis / Q000187:drug effects; D015232:Dinoprostone / Q000494:pharmacology; D005269:Femur / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism*; D019833:Genistein / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D005947:Glucose / Q000032:analysis / Q000378:metabolism; D007529:Isoflavones / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D019344:Lactic Acid / Q000032:analysis / Q000096:biosynthesis; D008297:Male; D010281:Parathyroid Hormone / Q000494:pharmacology; D010766:Phosphorylation; D051381:Rats; D017208:Rats, Wistar
D007529:Isoflavones; D010281:Parathyroid Hormone; D019344:Lactic Acid; C004742:daidzein; D004247:DNA; D003513:Cycloheximide; D019833:Genistein; D000469:Alkaline Phosphatase; D005947:Glucose; D015232:Dinoprostone; D002118:Calcium